Risk of overall mortality in COVID-19 patients was lower in the second wave, compared with the first wave. However, cumulative incidences of thrombotic complications remained high in the second wave.
A subanalysis of COLCOT showed that initiation of colchicine within the first 3 days after MI significantly reduced the risk of an ischemic CV event compared to patients on placebo.
In a contemporary primary prevention cohort, MI and ASCVD event rates increased with higher LDL-c and older age. NNT to prevent one MI or ASCVD event was lower in people aged 70-100 years compared to younger individuals.
The ACC Expert Consensus Decision Pathway (ECDP) for optimization of HFrEF treatment provides practical guidance for physicians in managing patients with HFrEF. The 2017 ECDP has now been updated.
Patients with HF admitted to hospital for COVID-19 had increased risk for in-hospital mortality and needed more often ICU care and intubation and mechanical ventilation compared to patients without HF.
This position paper discusses the cause and consequences of endothelial injury and dysfunction in COVID-19.
After initiation of sacubitril/valsartan in HFrEF patients, ANP levels increased. Larger early increase in ANP was associated with improvements of measures of reverse cardiac remodeling.
Although relative risk for MI per 1 mmol/L higher LDL-c is similar across age groups, absolute risk for MI and ASCVD per LDL categories is much higher in individuals 80-100 years compared to those <70 years.
This phase 2 trial showed that ANGPTL3 inhibition by evinacumab significantly reduced LDL-c by ~50% at maximum dose in patients with refractory hypercholesterolemia.
Global CVD burden has increased in almost all regions outside high-income countries. The increase was largely due to population growth and aging. In addition, attribution of risk factors like SBP, BMI, and dietary risk increased worldwide.
The AFFIRM-AHF trial showed that treatment with IV ferric carboxymaltose (FCM) in patients stabilized after acute HF and with concomitant iron deficiency reduced hospitalization due to HF.
A study using data from the Copenhagen General Population Study showed that cholesterol in VLDL explains 50% of the increased risk from apoB-containing lipoproteins to MI, and triglycerides in VLDL explain 0%. With poll.